Počet záznamů: 1
Endothelin type A receptor blockade attenuates aorto-caval fistula-induced heart failure in rats with angiotensin II-dependent hypertension
- 1.
SYSNO ASEP 0570226 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Endothelin type A receptor blockade attenuates aorto-caval fistula-induced heart failure in rats with angiotensin II-dependent hypertension Tvůrce(i) Kala, P. (CZ)
Gawrys, O. (CZ)
Miklovič, M. (CZ)
Vaňourková, Z. (CZ)
Škaroupková, P. (CZ)
Jíchová, Š. (CZ)
Sadowski, J. (PL)
Kompanowska - Jezierska, E. (PL)
Walkowska, A. (PL)
Veselka, J. (CZ)
Táborský, M. (CZ)
Maxová, H. (CZ)
Vaněčková, Ivana (FGU-C) RID, ORCID
Červenka, L. (CZ)Celkový počet autorů 14 Zdroj.dok. Journal of Hypertension. - : Lippincott Williams & Wilkins - ISSN 0263-6352
Roč. 41, č. 1 (2023), s. 99-114Poč.str. 16 s. Jazyk dok. eng - angličtina Země vyd. GB - Velká Británie Klíč. slova endothelin system ; hypertension ; Ren-2 renin transgenic rat ; renin-angiotensin system ; volume-overload heart failure Obor OECD Cardiac and Cardiovascular systems CEP LX22NPO5104 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy Způsob publikování Open access Institucionální podpora FGU-C - RVO:67985823 UT WOS 000921029000013 EID SCOPUS 85143180046 DOI 10.1097/HJH.0000000000003307 Anotace Objective:Evaluation of the effect of endothelin type A (ETA) receptor blockade on the course of volume-overload heart failure in rats with angiotensin II-dependent hypertension.Methods:Ren-2 renin transgenic rats (TGR) were used as a model of hypertension. Heart failure was induced by creating an aorto-caval fistula (ACF). Selective ETA receptor blockade was achieved by atrasentan. For comparison, other rat groups received trandolapril, an angiotensin-converting enzyme inhibitor (ACEi). Animals first underwent ACF creation and 2 weeks later the treatment with atrasentan or trandolapril, alone or combined, was applied, the follow-up period was 20 weeks.Results:Eighteen days after creating ACF, untreated TGR began to die, and none was alive by day 79. Both atrasentan and trandolapril treatment improved the survival rate, ultimately to 56% (18 of 31 animals) and 69% (22 of 32 animals), respectively. Combined ACEi and ETA receptor blockade improved the final survival rate to 52% (17 of 33 animals). The effects of the three treatment regimens on the survival rate did not significantly differ. All three treatment regimens suppressed the development of cardiac hypertrophy and lung congestion, decreased left ventricle (LV) end-diastolic volume and LV end-diastolic pressure, and improved LV systolic contractility in ACF TGR as compared with their untreated counterparts.Conclusion:The treatment with ETA receptor antagonist delays the onset of decompensation of volume-overload heart failure and improves the survival rate in hypertensive TGR with ACF-induced heart failure. However, the addition of ETA receptor blockade did not enhance the beneficial effects beyond those obtained with standard treatment with ACEi alone. Pracoviště Fyziologický ústav Kontakt Lucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400 Rok sběru 2024 Elektronická adresa https://journals.lww.com/jhypertension/Fulltext/2023/01000/Endothelin_type_A_receptor_blockade_attenuates.11.aspx
Počet záznamů: 1